氨糖在骨关节炎中的应用
合集下载
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
killer NSAIs cause serious gastrointestinal and cardiovascular
adverse events, especially with long term use Glucosamine was used to be thought as disease modifying
Effects of glucosamine in patients with osteoarthritis
2016级硕士研究生：
研究生导师： 周宗科教授
June, 2018
Introduction
Osteoarthritis of hip and knee is increasing non-steroidal anti-inflammatory drugs was used as the pain
Method
Statistical analysis: multivariable Bayesian hierarchical random effects models
Significant difference: we back transformed effect sizes to differences on a 10 cm visual analogue scale on the basis of a median pooled SD of 2.5 cm found in large scale osteoarthritis trials that assessed pain on a 10 cm visual analogue scale.
Result
Result
Result
Result
tests for interaction were all negative (P≥0.20 for interaction)
Result
Joint space: The difference was -0.2 mm (-0.3 to 0.0 mm) in glucosamine -0.1 mm (-0.3 to 0.1 mm) in favour of chondroitin 0.0 mm (-0.2 to 0.2 mm) for the combination
agents and recommended for years Global sales：$2bn (£1.3bn, €0.8bn) in 2008, 60% compared
with 2003, 2013 reaching $2.3bn Results from randomized trials about the effectiveness ofConcl Nhomakorabeasion
We believe it unlikely that future trials will show a clinically relevant benefit of any of the evaluated preparations
Our findings indicate that glucosamine, chondroitin, and their combination do not result in a relevant reduction of joint pain nor affect joint space narrowing compared with placebo.
We prespecified a minimal clinically important difference of 0.37 SD units, corresponding to 0.9 cm on a 10 cm visual analogue scale.
joint space clinically important difference : SD of 1.2 mm
Limitations
Meta-analysis heterogeneity between trials needed to be considered inconsistency between direct and indirect comparisons
Some patients, however, are convinced that these preparations are beneficial, which might be because of the natural course of osteoarthritis, regression to the mean, or the placebo effect
chondroitin and glucosamine are conflicting
Article #1
2010 . BMJ Impactor 20.75
Article #1
Aim: To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee
more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head General character: 10 trials in 3803 patients were included.
Design: network meta-analysis Outcomes: pain release, change in minimal width of joint space Eligibility criteria: Large scale randomized controlled trials in
adverse events, especially with long term use Glucosamine was used to be thought as disease modifying
Effects of glucosamine in patients with osteoarthritis
2016级硕士研究生：
研究生导师： 周宗科教授
June, 2018
Introduction
Osteoarthritis of hip and knee is increasing non-steroidal anti-inflammatory drugs was used as the pain
Method
Statistical analysis: multivariable Bayesian hierarchical random effects models
Significant difference: we back transformed effect sizes to differences on a 10 cm visual analogue scale on the basis of a median pooled SD of 2.5 cm found in large scale osteoarthritis trials that assessed pain on a 10 cm visual analogue scale.
Result
Result
Result
Result
tests for interaction were all negative (P≥0.20 for interaction)
Result
Joint space: The difference was -0.2 mm (-0.3 to 0.0 mm) in glucosamine -0.1 mm (-0.3 to 0.1 mm) in favour of chondroitin 0.0 mm (-0.2 to 0.2 mm) for the combination
agents and recommended for years Global sales：$2bn (£1.3bn, €0.8bn) in 2008, 60% compared
with 2003, 2013 reaching $2.3bn Results from randomized trials about the effectiveness ofConcl Nhomakorabeasion
We believe it unlikely that future trials will show a clinically relevant benefit of any of the evaluated preparations
Our findings indicate that glucosamine, chondroitin, and their combination do not result in a relevant reduction of joint pain nor affect joint space narrowing compared with placebo.
We prespecified a minimal clinically important difference of 0.37 SD units, corresponding to 0.9 cm on a 10 cm visual analogue scale.
joint space clinically important difference : SD of 1.2 mm
Limitations
Meta-analysis heterogeneity between trials needed to be considered inconsistency between direct and indirect comparisons
Some patients, however, are convinced that these preparations are beneficial, which might be because of the natural course of osteoarthritis, regression to the mean, or the placebo effect
chondroitin and glucosamine are conflicting
Article #1
2010 . BMJ Impactor 20.75
Article #1
Aim: To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee
more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head General character: 10 trials in 3803 patients were included.
Design: network meta-analysis Outcomes: pain release, change in minimal width of joint space Eligibility criteria: Large scale randomized controlled trials in